Под нашим наблюдением находилось 10 недоношенных новорожденных, получавших Эритропоетин и 30 недоношенных новорожденных которые лечились только препаратами железа и витамином Е. Эритропоетин был назначен в конце первой недели жизни ребенка в дозе 600ЕД\кг в неделю, в 3 приема подкожно в течении 6 недель. Лечение железом также было начато в конце 1 недели жизни в дозе 0.5мг\кг в день, с повышением дозы до 7-8мг\ кг в день, также назначена фолиевая кислота 2.5мг\ день и витамин Е 15 мг\день. Лечение было начато когда ентеральное питание составило 20 мл\кг день. В контрольной группе лечение было начато на 1 неделе жизни препаратами железа(6 мг\кг в день) фолиевая кислота 2.5мг\день и витамин Е 15 мг\день. Мониторинг осуществляли путем определения гематологических параметров (гемоглобин, гематокрит, ретикулоциты) на 10 день, в 1 месяц, 2 месяца, 37 недель гестационного возраста. В динамике в группе лечения было обнаружено снижение гемоглобина на 10 день жизни, а начиная с месяца наметилась тен- денция к росту. Также пронаблюдали значительное снижение гемоглобина (p<0.001) у новорожденных которые не получали Эритропоетин гемоглобин оставался на таком же уровне. Значительные отличия между 1 и 2 группами на- блюдаются после 1 месяца лечения и становятся более значительными в 2 месяца.

The study wants to perform the evaluation of the hemoglobine, hematocrite, the reticulocytes, the number of precociuos anemy and late transfusions in 10 prematures with very low birthweight infants from birth to two months of live which received the treatment with erythropoietin against 30 very-low birthweight infants with the same antropometrics parameters which received only iron treatment. The treatment was started at the end of the fi rst week of life with dozes of 600 UN/KG/WEEK, divided in 3 dozes, subcutaneus in term of 6 weeks or untill 37 weeks of gestation. The treatment with iron drugs was started at end of fi rst weeks of life with dose of 0.5 mg/kg/day with progressive increasing of dozes to, 6-8 mg/kg/day at 10-15 day. Iron’s drug treatment was folic ac. 2.5 mg/day and vitamin E 15 mg/day. The treatment was initiated when enteral nutrition was over 20ml/kg/ day and>75Kcal/kg/day Control group treatment started with iron drug at 3 weeks of life 6 mg/kg/day, folic ac. 2.5 mg/kg/day and vitamin E. Monitoring process was based on evaluation of hematological parameters HB, HT, reticolocyte at 10 days, 1 moth, 2 moths, 37 weeks postconceptional. Early hemotransfusion was and at considering until 15 days of life and late hemotransfusion after 16 days of the postnatal period. In dynamic of the postnatal period was observed group in whith decreasing of HB was started at 10 days until 1 month of life when the process was stabilized. Meantime we observed a statistical decrease of HB (0.0001) at 1 month of life in the group without treatment . HT have a similar evolution, without statistical differences at birthday, but with statistical difference at 1 month of life (p=0.001).The statistical differences between 2 groups was established at 1 month of live with a higher level of HB, HT in group which received Erythropoietin. At 2 month of life and 37 weeks of gestation the values diferenced are lower. And number reticulocyte represents higher value in group in which treatment was performys much more at those with treatment, the diferences it is present untill 37 weeks postconceptional Treatment with eritropoetine semnifi catife reduce lower value of HB and HT and reduce late hemotransfusion in newborns very low weight at birth. Treatment with eritropetina is benefi c and reduce the necessety in transfusion in newborn.